Gastrectomy Clinical Trial
Official title:
A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy
Verified date | August 2012 |
Source | Anhui Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Interventional |
Clinically, combining epidural with general anaesthesia may confer many advantages to patients undergoing major thoracic, abdominal or orthopaedic surgery. Epidural anaesthesia can attenuate sympathetic hyperactivity and the stress response, maintain bowel peristalsis, spare the use of opioids, and facilitate postoperative feeding and physiotherapy. However, establishing epidural anesthesia is not without risks and contraindications, including refusal by the patient, technical failure, unintentional dural puncture, waist and back pain and local anaesthetic toxicity. When neurologic complications do occur, the resulting morbidity and mortality is considerable. Dexmedetomidine is a potent α2-adrenoceptor agonist with an 8 times greater affinity for α2-adrenoceptors than clonidine. This class of agent is known to have sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.1 Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage. The investigators hypothesize that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | July 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Consent - ASA 1-2 - No contraindication to epidural or dexmedetomidine - First time surgery for current conditions - Not on chronic pain medications or sedative Exclusion Criteria: - .The subject has known significant renal or hepatic disorders determined by medical history, physical examination or laboratory tests - The subject has a known or suspected allergy to opioid analgesics or dexmedetomidine - The subject has history of. cardiovascular issues which would preclude the use of dexmedetomidine - The subject has know central nervous system disease or neurological impairment - The subject is an ASA classification of 3 or greater |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital of Anhui Medical University | HeFei | Anhui |
Lead Sponsor | Collaborator |
---|---|
Anhui Medical University |
China,
Kunisawa T, Nagata O, Nagashima M, Mitamura S, Ueno M, Suzuki A, Takahata O, Iwasaki H. Dexmedetomidine suppresses the decrease in blood pressure during anesthetic induction and blunts the cardiovascular response to tracheal intubation. J Clin Anesth. 2009 May;21(3):194-9. doi: 10.1016/j.jclinane.2008.08.015. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiovascular Parameters: Heart rate, blood pressure and ECG ;Parameters on stress response:norepinephrine (NE), epinephrine ( E) | pre-administration of Dex or epidural anesthesia,intubation, 3 min after intubation , immediately after incision, immediately after the initiation of celiac exploration, 1 h after operation,extubation | Yes | |
Secondary | Anesthetics consumption: propofol and remifentanil consumption | during operation | Yes | |
Secondary | anesthesia recovery :the time of eye opening, side effects such as nausea, vomiting and post-anaesthetic shivering, VAS, first exhaust time, hospitalization time | up to 48 hours | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04422236 -
A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery
|
||
Completed |
NCT00827931 -
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
|
Phase 4 | |
Completed |
NCT01257711 -
A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
|
N/A | |
Not yet recruiting |
NCT06062225 -
Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy
|
N/A | |
Completed |
NCT00885781 -
Efficacy and Safety Comparison Between SMOFlipid and Lipovenoes MCT
|
Phase 4 | |
Not yet recruiting |
NCT05071755 -
Gastrectomy Outcomes in Elderly Patients
|
||
Recruiting |
NCT04798820 -
The Effect of Intensive Dietary Education on Nutritional Status After Gastrectomy(SING)
|
N/A | |
Not yet recruiting |
NCT04191564 -
Effect of Anesthetic Conditions on Stapling Thickness and Quality
|
N/A | |
Recruiting |
NCT04295473 -
Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
|
N/A | |
Recruiting |
NCT02068833 -
Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study
|
N/A | |
Recruiting |
NCT01142271 -
Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy
|
Phase 3 | |
Completed |
NCT03939819 -
Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy
|
N/A | |
Withdrawn |
NCT00622804 -
Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy
|
Phase 3 | |
Recruiting |
NCT03708783 -
Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC
|
N/A | |
Recruiting |
NCT06403540 -
The Impact of Laparotomy and Analgesia Methods on Diaphragm
|
||
Completed |
NCT03436082 -
Post-Market Surveillance With a Novel mHealth Platform
|
||
Recruiting |
NCT06058442 -
The Pancreatic Enzymes After Gastrectomy Trial
|
Phase 3 | |
Terminated |
NCT02836353 -
Metabolic Consequences of Gastrointestinal Surgery
|
N/A | |
Unknown status |
NCT02503826 -
The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery
|
Phase 4 |